Stannsoporfin
- Generic Name
- Stannsoporfin
- Drug Type
- Small Molecule
- Chemical Formula
- C34H36Cl2N4O4Sn
- CAS Number
- 106344-20-1
- Unique Ingredient Identifier
- 0KAE1U0G7Q
Overview
Stannsoporfin is a competitive heme oxygenase (HO) inhibitor being developed by InfaCare, a subsidiary of WellSpring Pharmaceuticals, for the prevention of hyperbilirubinemia in infants at risk of developing jaundice.
Background
Stannsoporfin is a competitive heme oxygenase (HO) inhibitor being developed by InfaCare, a subsidiary of WellSpring Pharmaceuticals, for the prevention of hyperbilirubinemia in infants at risk of developing jaundice.
Indication
Investigated for use/treatment in liver disease, metabolic disease, and pediatric indications.
Associated Conditions
No associated conditions information available.
Clinical Trials
FDA Approved Products
No FDA products found for this drug
Singapore Approved Products
No Singapore products found for this drug
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.
© Copyright 2025. All Rights Reserved by MedPath